menu
    • menu

    Find Trastuzumab manufacturers, exporters & distributors on PharmaCompass

    LGM Trastuzumab

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    12

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    1

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    9

    Listed Suppliers

    Other Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    209

    FDF Dossiers

    FDF Dossiers

    11

    FDA Orange Book

    FDA (Orange Book)

    65

    Europe

    Europe

    16

    Canada

    Canada

    106

    Australia

    Australia

    8

    South Africa

    South Africa

    3

    Listed Dossiers

    Listed Dossiers

    394DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    10RELATED EXCIPIENT COMPANIES

    19EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    38

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 3,808,443

    GLOBAL SALES INFORMATION

    US Medicaid

    27,006,261

    Annual Reports

    56,150

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    4

    API

    10

    FDF

    DIGITAL CONTENT

    3

    Data Compilation #PharmaFlow

    1

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    342

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1647282600,"product":"TRASTUZUMAB(R-DNA ORIGIN) DRUG SUBSTANCE","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"SAN FRANCISCO, CA","customer":"EUROFINS ADVANTAR LABORATORIESINC","customerCountry":"UNITED STATES","quantity":"0.06","actualQuantity":"59.9","unit":"GMS","unitRateFc":"3895","totalValueFC":"228169.9","currency":"USD","unitRateINR":290333.88981636061,"date":"15-Mar-2022","totalValueINR":"17391000","totalValueInUsd":"228169.9","indian_port":"HYDERABAD AIR","hs_no":"29379020","bill_no":"8949822","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1688322600,"product":"TRASTUZUMAB DRUG SUBSTANCE(QTY:5 GMS)(FO","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"LONDON - HEATHROW","customer":"DR REDDY'S LABORATORIES","customerCountry":"UNITED KINGDOM","quantity":"0.01","actualQuantity":"5","unit":"GMS","unitRateFc":"3286","totalValueFC":"16121.3","currency":"USD","unitRateINR":265000.0626,"date":"03-Jul-2023","totalValueINR":"1325000.313","totalValueInUsd":"16121.3","indian_port":"HYDERABAD AIR","hs_no":"29379020","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED KINGDOM","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725042600,"product":"TRASTUZUMAB DRUG SUBSTANCE(36.4MG\/ML X 50ML)(1.820 GMS)","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"VNUKOVO","customer":"JSC R PHARM","customerCountry":"RUSSIA","quantity":"0.00","actualQuantity":"1.82","unit":"GMS","unitRateFc":"1205","totalValueFC":"1892.1","currency":"USD","unitRateINR":87200.88461538461,"date":"31-Aug-2024","totalValueINR":"158705.61","totalValueInUsd":"1892.1","indian_port":"Hyderabad Air","hs_no":"29379020","bill_no":"3660208","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""}]
    15-Mar-2022
    31-Aug-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

    Details:

    Tesevatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.


    Lead Product(s): Tesevatinib,Trastuzumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 03, 2014

    Sanofi Company Banner

    01

    Sanofi

    France
    arrow
    AES
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Tesevatinib,Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast...

    Details : Tesevatinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    June 03, 2014

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed o...

    Details:

    XL147 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.


    Lead Product(s): XL147,Trastuzumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 06, 2010

    Sanofi Company Banner

    02

    Sanofi

    France
    arrow
    AES
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : XL147,Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjec...

    Details : XL147 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    January 06, 2010

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Prestige Biopharma, Biosidus in Exclusive License for Tuznue® in Latin America

    Details:

    Through the licensing deal for Trastuzumab, an unconjugated antibody targeting receptor protein-tyrosine kinase erbB-2, the agreement aims to advance breast cancer treatment.


    Lead Product(s): Trastuzumab,Inapplicable

    Therapeutic Area: Oncology Brand Name: Tuznue

    Study Phase: Approved FDFProduct Type: Antibody, Unconjugated

    Sponsor: Biosidus

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement November 26, 2025

    blank

    03

    Prestige BioPharma Pte Ltd

    Singapore
    arrow
    AES
    Not Confirmed

    Prestige BioPharma Pte Ltd

    Singapore
    arrow
    AES
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Biosidus

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Prestige Biopharma, Biosidus in Exclusive License for Tuznue® in Latin America

    Details : Through the licensing deal for Trastuzumab, an unconjugated antibody targeting receptor protein-tyrosine kinase erbB-2, the agreement aims to advance breast cancer treatment.

    Product Name : Tuznue

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    November 26, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Teva, Prestige Biopharma Sign License Deal for Tuznue® in Europe

    Details:

    The collaboration aims to advance the clinical development of Trastuzumab, an unconjugated antibody targeting the receptor protein-tyrosine kinase erbB-2 in breast cancer.


    Lead Product(s): Trastuzumab,Inapplicable

    Therapeutic Area: Oncology Brand Name: Tuznue

    Study Phase: Approved FDFProduct Type: Antibody, Unconjugated

    Sponsor: Prestige BioPharma Pte Ltd

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration October 20, 2025

    blank

    04

    Teva Pharmaceutical Industries

    Israel
    arrow
    AES
    Not Confirmed

    Teva Pharmaceutical Industries

    Israel
    arrow
    AES
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Prestige BioPharma Pte Ltd

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Teva, Prestige Biopharma Sign License Deal for Tuznue® in Europe

    Details : The collaboration aims to advance the clinical development of Trastuzumab, an unconjugated antibody targeting the receptor protein-tyrosine kinase erbB-2 in breast cancer.

    Product Name : Tuznue

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    October 20, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

    Details:

    FT836 is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.


    Lead Product(s): FT836,Paclitaxel,Cetuximab,Trastuzumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Cell & Gene Therapy

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 14, 2025

    blank

    05

    Fate Therapeutics

    U.S.A
    arrow
    AES
    Not Confirmed

    Fate Therapeutics

    U.S.A
    arrow
    AES
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FT836,Paclitaxel,Cetuximab,Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Sol...

    Details : FT836 is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

    Product Name : Undisclosed

    Product Type : Cell & Gene Therapy

    Upfront Cash : Inapplicable

    October 14, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years

    Details:

    Laroprovstat is a Miscellaneous drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Laroprovstat,Paclitaxel,Cetuximab,Trastuzumab

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: PAREXEL International Corporation

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 14, 2025

    blank

    06

    AstraZeneca

    United Kingdom
    arrow
    AES
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    AES
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Laroprovstat,Paclitaxel,Cetuximab,Trastuzumab

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : PAREXEL International Corporation

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunt...

    Details : Laroprovstat is a Miscellaneous drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 14, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants

    Details:

    Trastuzumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Breast Neoplasms.


    Lead Product(s): Trastuzumab,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 09, 2025

    blank

    07

    Genentech

    U.S.A
    arrow
    AES
    Not Confirmed

    Genentech

    U.S.A
    arrow
    AES
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms ...

    Details : Trastuzumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Breast Neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    October 09, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

    Details:

    Tucatinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.


    Lead Product(s): Tucatinib,Trastuzumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Pfizer Inc | Eurofins CDMO | UNICANCER

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 25, 2025

    blank

    08

    Institut Curie

    Country
    arrow
    AES
    Not Confirmed

    Institut Curie

    Country
    arrow
    AES
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tucatinib,Trastuzumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Pfizer Inc | Eurofins CDMO | UNICANCER

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

    Details : Tucatinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    September 25, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

    Details:

    Trastuzumab Rezetecan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.


    Lead Product(s): Trastuzumab Rezetecan,Pyrotinib,Dalpiciclib,Trastuzumab,Letrozole,Anastrozole,Exemestane,Fulvestrant,Leuprolide Acetate,Goserelin Acetate

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody-drug Conjugate

    Sponsor: Jiangsu Hengrui Medicine | Chinese PLA General Hospital

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 18, 2025

    blank

    09

    Fudan University

    Country
    arrow
    AES
    Not Confirmed

    Fudan University

    Country
    arrow
    AES
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab Rezetecan,Pyrotinib,Dalpiciclib,Trastuzumab,Letrozole,Anastrozole,Exemestane,Fulvestrant,Leuprolide Acetate,Goserelin Acetate

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Jiangsu Hengrui Medicine | Chinese PLA General Hospital

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A...

    Details : Trastuzumab Rezetecan is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    September 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

    Details:

    Dazublys (trastuzumab) is a monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast cancer.


    Lead Product(s): Trastuzumab,Inapplicable

    Therapeutic Area: Oncology Brand Name: Dazublys

    Study Phase: Approved FDFProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 26, 2025

    blank

    10

    CuraTeQ Biologics

    India
    arrow
    AES
    Not Confirmed

    CuraTeQ Biologics

    India
    arrow
    AES
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Trastuzumab,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

    Details : Dazublys (trastuzumab) is a monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast cancer.

    Product Name : Dazublys

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    August 26, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Parenteral

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Topical

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    STOCK RECAP #PipelineProspector

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search